Ausgabe 2/2017
Inhalt (15 Artikel)
Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies
Alexandra Tyulyandina, Daniel Harrison, Wei Yin, Evgenia Stepanova, Dmitry Kochenkov, Eliso Solomko, Nina Peretolchina, Frits Daeyaert, Jean-Baptiste Joos, Koen Van Aken, Mikhail Byakhov, Evgenia Gavrilova, Sergei Tjulandin, Ilya Tsimafeyeu
Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species
Alycen P. Lundberg, Joshua M. Francis, Malgorzata Pajak, Elizabeth I. Parkinson, Kathryn L. Wycislo, Thomas J. Rosol, Megan E. Brown, Cheryl A. London, Levent Dirikolu, Paul J. Hergenrother, Timothy M. Fan
Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice
Ming Hui Liew, Salby Ng, Chii Chii Chew, Teng Wai Koo, Yun Lee Chee, Evelyn Li-Ching Chee, Pilar Modamio, Cecilia Fernández, Eduardo L. Mariño, Ignacio Segarra
Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth
Sagar Shelake, Umesh T. Sankpal, W. Paul Bowman, Matthew Wise, Anish Ray, Riyaz Basha
Zebrafish phenotypic screen identifies novel Notch antagonists
Vithya Velaithan, Kazuhide Shaun Okuda, Mei Fong Ng, Norazwana Samat, Sze Wei Leong, Siti Munirah Mohd Faudzi, Faridah Abas, Khozirah Shaari, Sok Ching Cheong, Pei Jean Tan, Vyomesh Patel
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
Muhammad S. Beg, Andrew J. Brenner, Jasgit Sachdev, Mitesh Borad, Yoon-Koo Kang, Jay Stoudemire, Susan Smith, Andreas G. Bader, Sinil Kim, David S. Hong
A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
James M. Cleary, Lee S. Rosen, Kenichiro Yoshida, Drew Rasco, Geoffrey I. Shapiro, Weijing Sun
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors
Luis Paz-Ares, Martin Forster, Valentina Boni, Sergio Szyldergemajn, Jesús Corral, Samantha Turnbull, Antonio Cubillo, Carlos Fernandez Teruel, Iker López Calderero, Mariano Siguero, Patrick Bohan, Emiliano Calvo
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
Noboru Yamamoto, Hiroshi Nokihara, Yasuhide Yamada, Takashi Shibata, Yosuke Tamura, Yoshitaka Seki, Kazunori Honda, Yuko Tanabe, Hiroshi Wakui, Tomohide Tamura
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy
Yuichi Tambo, Yukio Hosomi, Hiroshi Sakai, Naoyuki Nogami, Shinji Atagi, Yasutsuna Sasaki, Terufumi Kato, Toshiaki Takahashi, Takashi Seto, Makoto Maemondo, Hiroshi Nokihara, Ryo Koyama, Kazuhiko Nakagawa, Tomoya Kawaguchi, Yuta Okamura, Osamu Nakamura, Makoto Nishio, Tomohide Tamura
A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016)
Satoru Miura, Makoto Maemondo, Akira Iwashima, Toshiyuki Harada, Shunichi Sugawara, Kunihiko Kobayashi, Akira Inoue, Taku Nakagawa, Yuichi Takiguchi, Hiroshi Watanabe, Takashi Ishida, Masaki Terada, Hiroshi Kagamu, Akihiko Gemma, Hirohisa Yoshizawa
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C
Khaldoun Almhanna, Maria Luisa Limon Miron, David Wright, Antonio Cubillo Gracian, Richard A. Hubner, Jean-Luc Van Laethem, Carolina Muriel López, Maria Alsina, Frederico Longo Muñoz, Johanna Bendell, Irfan Firdaus, Wells Messersmith, Zhan Ye, Adedigbo A. Fasanmade, Hadi Danaee, Thea Kalebic
Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old
Frederic Bigot, Pascaline Boudou-Rouquette, Jennifer Arrondeau, Audrey Thomas-Schoemann, Camille Tlemsani, Jeanne Chapron, Olivier Huillard, Anatole Cessot, Michel Vidal, Jerome Alexandre, Benoit Blanchet, Francois Goldwasser
Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors
Pierre Loulergue, Mansouria Merad, Romain Coriat, Michel Ducreux, David Planchard, Valérie Boige, Axel Le Cesne, Thomas M. Gregory, Vianney Poinsignon, Angelo Paci, Olivier Mir
Erratum to: Zebrafish phenotypic screen identifies novel Notch antagonists
Vithya Velaithan, Kazuhide Shaun Okuda, Mei Fong Ng, Norazwana Samat, Sze Wei Leong, Siti Munirah Mohd Faudzi, Faridah Abas, Khozirah Shaari, Sok Ching Cheong, Pei Jean Tan, Vyomesh Patel